Cargando…
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies
Bladder cancer ranks as the 10th most common cancer type globally, and muscle-invasive disease accounts for approximately 25% of newly diagnosed bladder cancers. Despite definitive treatment, 50% of patients with muscle-invasive bladder cancer (MIBC) develop metastasis within 2 years, leading to dea...
Autores principales: | Kim, Kyung Hwan, Lee, Hye Won, Ha, Hong Koo, Seo, Ho Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172053/ https://www.ncbi.nlm.nih.gov/pubmed/37341001 http://dx.doi.org/10.4111/icu.20230006 |
Ejemplares similares
-
Perioperative immunotherapy in muscle-invasive bladder cancer
por: Lee, Hyung Ho, et al.
Publicado: (2020) -
Emerging perioperative therapeutic approaches in muscle invasive bladder cancer
por: Patil, Goutham, et al.
Publicado: (2022) -
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2023) -
Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020) -
Perioperative therapy in muscle invasive bladder cancer
por: Chatterjee, Ambarish, et al.
Publicado: (2021)